<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2014060717998N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2014-08-16</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>The Effect of Melissa Officinalis Capsules and Health Care Educational Program on the Severity of the Symptoms of Premenstrual Syndrome</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the Effect of Melissa Officinalis Capsules and Health Care Educational Program on the Severity of the Symptoms of Premenstrual Syndrome in High School Girl Students in Shiraz</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2004-01-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>800</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/16427</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: N/A, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Premensstural Syndrom.</hc_freetext>
      <i_freetext>Intervention 1: In the control group who receive placebo: The participants take a dosage of 1200 mg per day taken as 2 capsules of 600 mg from the first day of the menstrual cycle for 3 cycles. Researcher calls the research unit at least 3 to 4 times and talks to them call them for guidance. Capsules are given to the students monthly. The participants complete the questionnaires at the end of each month. Intervention 2: In the experimental group who attend health care educational program: The participants attend an educational program consisted of six two-hour educational sessions. The students complete the awareness and insight questionnaire once at the beginning of the program and once at the end of the 6th session. Intervention 3: In the control group of the educational program: The participants only complete the awareness and insight questionnaire. Intervention 4: In the experimental group who receive Melissa officinalis capsules: The participants take a dosage of 1200 mg per day mg taken as 2 capsules of 600 mg from the first day of the menstrual cycle for 3 cycles. Researcher calls the research unit at least 3 to 4 times and talks to them call them for guidance. Capsules are given to the students monthly. The participants complete the questionnaires at the end of each month.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Marzieh Akbarzadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>College of Nursing and Midwifery, Nemazee square</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>713451978</zip>
        <telephone>+98 71 1647 4254</telephone>
        <email>akbarzadehmarzieh@yahoo.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Marzieh Akbarzadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>College of Nursing and Midwifery, Nemazee square</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>713451978</zip>
        <telephone>+98 71 1647 4254</telephone>
        <email>akbarzadehmarzieh@yahoo.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: willingness to participate in the study, obtaining informed consent from the parents of the students, not being in any stressful situation at the time of enrollment or during the study, presence in the educational sessions, not consuming vitamin supplements at the time of enrollment, not consuming hormonal medications such as contraceptives for at least 2 months before or during the study, a menstrual period of 3 to 7 days, lack of any underlying diseases such as thyroid diseases, diabetes mellitus and psychiatric disease. Exclusion criteria: the children’s willingness to leave the study, the request of the parents for exclusion of their children from the study, occurrence of a stressful event for the students or their parents during the study, absence of more than 2 sessions in group interactions and not compensating for missed sessions by participating in the sessions of other groups, consuming any medications during the study, any changes in the menstrual period (less than 3 days and more than 7 days), any changes in menstrual cycle length (less than 24 days and more than 35 days) and having stress during the study or in the last 3 months (such as death of the relatives, marriage or undergoing any surgical procedure).</inclusion_criteria>
      <agemin>76 years</agemin>
      <agemax>72 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N94.3</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Premenstrual tension syndrome</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Placebo</i_code>
      <i_code>Prevention</i_code>
      <i_code>N/A</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>In the control group who receive placebo: The participants take a dosage of 1200 mg per day taken as 2 capsules of 600 mg from the first day of the menstrual cycle for 3 cycles. Researcher calls the research unit at least 3 to 4 times and talks to them call them for guidance. Capsules are given to the students monthly. The participants complete the questionnaires at the end of each month.</i_keyword>
      <i_keyword>In the experimental group who attend health care educational program: The participants attend an educational program consisted of six two-hour educational sessions. The students complete the awareness and insight questionnaire once at the beginning of the program and once at the end of the 6th session.</i_keyword>
      <i_keyword>In the control group of the educational program: The participants only complete the awareness and insight questionnaire.</i_keyword>
      <i_keyword>In the experimental group who receive Melissa officinalis capsules: The participants take a dosage of 1200 mg per day mg taken as 2 capsules of 600 mg from the first day of the menstrual cycle for 3 cycles. Researcher calls the research unit at least 3 to 4 times and talks to them call them for guidance. Capsules are given to the students monthly. The participants complete the questionnaires at the end of each month.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Mental and emotional symptoms of premenstrual syndrome. Timepoint: In the second step before the intervention and at the end of each month after the intervention (for 3 months). Method of measurement: Premenstrual Syndrome Screening Questionnaire.</prim_outcome>
      <prim_outcome>Physical symptoms of premenstrual syndrome. Timepoint: In the second step before the intervention and at the end of each month after the intervention (for 3 months. Method of measurement: Premenstrual Syndrome Screening Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Individual's general health especially mental health. Timepoint: Before the intervention. Method of measurement: General Health Questionnaire (G.H.Q).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2013-12-16</approval_date>
        <contact_name>Ethics Committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>Central building of Shiraz University of Medical Sciences  Shiraz, Zand Blvd. Shiraz  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
